3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Glioma
2
Wilms Tumor
1
Waldenstrom Macroglobulinemia
1
Sarcoma, Synovial
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Recurrence
1
Paraproteinemias
1
Osteosarcoma
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms, Neuroepithelial
1
Neoplasms
1
Multiple Myeloma
1
Medulloblastoma
1
Lymphoproliferative Disorders
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoproliferative Disorders
1
Hodgkin Disease
1
Hematologic Diseases
1
Gliosarcoma
1
Glioblastoma
1
Interventions
Magnetic Resonance Spectroscopy
6
X-Rays
5
Specimen Handling
5
Phantoms, Imaging
5
Nuclear Medicine Department, Hospital
5
Biopsy
5
Cyclophosphamide
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Temozolomide
2
Etoposide
2
tazemetostat
1
pembrolizumab
1
palbociclib
1
omburtamab I-131
1
olaparib
1
etoposide phosphate
1
dostarlimab
1
abemaciclib
1
Vemurafenib
1
Triiodothyronine
1
Surgical Procedures, Operative
1
Sirolimus
1
Radiation
1
Proton Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Ependymoma
×
CLR1404
×
Clear all
NCT03478462
2026-03-18
CLOVER-2
Cellectar Biosciences, Inc.
Phase 1
Active not recruiting
30 enrolled